Research Team at UNC Validates PixCell Medical’s HemoScreen as Game-Changer for Clozapine Monitoring in Psychiatry

A groundbreaking study conducted by a University of North Carolina (UNC) research team has unveiled compelling evidence supporting the adoption of PixCell Medical’s FDA-cleared Point-of-Care 5-part differential CBC analyzer, as the premier choice for psychiatric treatment and monitoring, specifically in the context of Clozapine therapy.

The research, which evaluated three point-of-care instruments for complete blood count analysis, has positioned HemoScreen as the optimal solution for the management of Clozapine treatment.

Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC). In an effort to find a clinically viable and simple-to-use CBC analyzer for frequent near-patient testing, a UNC research team assessed three CBC analyzers: Sight OLO, PixCell HemoScreen, and Sysmex pocH-100i, comparing them against the ADVIA 2120i and manual differential methods.

HemoScreen exhibited remarkable precision, outperforming other instruments, and demonstrating exceptional accuracy. Notably, HemoScreen excelled in clinical concordance, achieving a rate of 89.5% at medical decision thresholds for ANC, surpassing the other POC devices. This establishes HemoScreen as the most reliable choice in Clozapine therapy management.

Dr. Yaara Ben Yosef, PixCell Medical’s director of clinical affairs, emphasized; “This research demonstrates that HemoScreen is the superior choice for monitoring patients on Clozapine therapy. The high clinical concordance and exceptional accuracy of the HemoScreen make it an indispensable tool for healthcare professionals in managing the potential risks associated with Clozapine treatment.”

Additionally, HemoScreen’s ability to sample blood via a fingerstick (direct capillary sampling) offers a significant advantage, especially for psychiatry patients requiring weekly or monthly CBC testing as part of their Clozapine treatment management. The uniquely simple blood collection method and minimal discomfort of HemoScreen’s simple sampling procedure with near-patient on-the-spot results provide substantial benefits for treatment adherence and positive outcomes.

This groundbreaking research cements PixCell Medical’s HemoScreen as the gold standard for complete blood count analysis in Clozapine therapy. Healthcare providers can confidently rely on HemoScreen to ensure the safety and efficacy of Clozapine treatment for patients with treatment-resistant schizophrenia.

Medical Device News Magazine
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Michael Dabrowski, CEO of Pelago Bioscience "We are grateful to the University of Edinburgh in their acknowledgement of our Patent. I encourage the drug discovery community to engage with Pelago Bioscience to explore the value that our patented CETSA technology and services can bring to enhance their drug discovery efforts.
The Thermo Scientific™ Dionex™ Inuvion™ Ion Chromatography (IC) system, helping to make ion analysis simpler and more intuitive for labs of all sizes. The new analytical instrument is designed to be easily reconfigurable, providing those who require determination of ionic and small polar compounds with a one stop shop for consistent, reliable ion analysis.
This new collaboration is another example of Blacksmith's creative deal-making with top tier partners that bring expertise to the table which helps de-risk and accelerate scientific discoveries for the development of valuable products.
Heparin Sodium 2,000 units in 0.9% Sodium Chloride Injection 1,000 mL (2 units/mL), is indicated as an anticoagulant to maintain catheter patency.
Through this agreement, RaySearch acquires full ownership of all rights to the product DrugLog for its application in the field of oncology, including the measuring device, calibration parameters, source code, as well as intellectual property rights.

By using this website you agree to accept Medical Device News Magazine Privacy Policy